scholarly journals VARIANTS OF THYROID GLAND PATHOLOGY IN CHRONIC HEPATITIS C PATIENTS

2017 ◽  
Vol 22 (4) ◽  
pp. 172-177
Author(s):  
Marina A. Nikonorova ◽  
N. S Lubskaya ◽  
E. V Volchkova ◽  
E. A Nemilostiva ◽  
O. I Matros
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Thyroid Gland ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Autoimmune Thyroiditis ◽  
Thyroid Dysfunction ◽  
Thyroid Status ◽  
History Of ◽  
The Relationship

Introduction. HCV is the cause not only of cirrhosis, hepatocellular carcinoma, but also extrahepatic manifestations. Currently, HCV is considered as an independent risk factor for thyroid pathology. In recent years, the level of pathology of the thyroid gland in the Altai Territory has increased by 16.4 times, which determined the purpose of this study: to study the features of the thyroid status in patients with chronic hepatitis C (CHC) in the Altai Territory. Materials and methods. There was executed a prospective, dynamic clinical, laboratory and instrumental examination of 240 CHC patients (47,5% of men and 52,5% of women aged of from 18 to 50 years), 120 of whom had HCV (49,1% of men and 50,9% of women, aged of from 18 to 50 years, mean age: 41,1±9,91 years) who did not receive antiviral therapy (HTV), the pathology of the thyroid gland in them was established for the first time. The study included the assessment of the level of TSH, total and free T3, T4, antibodies to thyreperoxidase (APPO), ultrasound examination of the thyroid gland. The diagnosis of CHC is based on HCV RNA, anti-HCV (core, NS3-5), blood biochemistry, fibrosis level score according to Metavir (elastometry, PBP). Results of the study. In HCV patients there were revealed autoimmune thyroiditis (AIT) (5%), AIT with hypothyroidism (10%), AIT with latent hypothyroidism (8,3%), latent hypothyroidism (10%), hypothyroidism (16,6%), euthyroidism (49,1%) and thyrotoxicosis in only 1 patient. Variants of thyroid dysfunction were presented in the form of euthyroidism (60%), hypothyroidism (20%), hyperthyroidism (10%) and autoimmune thyroiditis (10%). The relationship between the development of the thyroid dysfunction (TD) and the history of the history of HCV infection has been established. Discussion and conclusions. CHC patients were more likely to have a history of euthyroidism and hypothyroidism. The relationship between TD and the duration of HCV infection can be regarded as its extrahepatic manifestation, and not as comorbid conditions. Thorough examination of the thyroid status it makes possible to identify TD people, which can be reflected in the choice of antiviral therapy and will determine the prognosis of the development of side effects.

scholarly journals Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C

2010 ◽  
Vol 2010 ◽  
pp. 1-9 ◽  
Author(s):  
Tatehiro Kagawa ◽  
Emmet B. Keeffe
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Natural History ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Long Term Results ◽  
Long Term Effects ◽  
History Of

Chronic hepatitis C is a major cause of chronic liver disease globally, and the natural history of progression may lead to cirrhosis with liver failure, hepatocellular carcinoma, and premature liver-related death. Emerging data demonstrates that interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with long-term persistence of SVR, improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy. This reduction in the rate of progression has also been demonstrated in patients with chronic hepatitis C and cirrhosis in some but not all studies. The majority of these results are reported with standard interferon therapy, and long-term results of peginterferon plus ribavirin therapy with a higher likelihood of SVR should have a yet greater impact on the population of treated patients. The impact on slowing progression is greatest in patients with an SVR, less in relapsers, and equivocal in nonresponders. Thus, the natural history of chronic hepatitis C after completion of antiviral therapy is favorable with achievement of an SVR, although further data are needed to determine the likely incremental impact of peginterferon plus ribavirin, late long-term effects of therapy, and the benefit of treatment in patients with advanced hepatic fibrosis.

Sa1300 Long-Term Impact of Antiviral Therapy in the Natural History of Chronic Hepatitis C

2014 ◽  
Vol 146 (5) ◽  
pp. S-256
Author(s):  
Patricia Cordero-Ruiz ◽  
Isabel Carmona-Soria ◽  
Angel Caunedo-Alvarez ◽  
Juan M Herrerias ◽  
Angel Vilches-Arenas
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Natural History ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
History Of ◽  
Long Term Impact

scholarly journals HEPATOCELLULAR CARCINOMA IN THE COHORT OF VIETNAMESE PATIENTS WITH CHRONIC HEPATITIS C

2018 ◽  
Vol 10 (3) ◽  
pp. 108-111
Author(s):  
N. Н. Chung ◽  
D. A. Lioznov ◽  
S. L. Nikolaenko
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Study Data ◽  
Response To Therapy ◽  
Hcv Infection ◽  
Screening Programs ◽  
History Of

Objectives. To describe the clinical and laboratory characteristics of chronic hepatitis C patients with hepatocellular carcinoma (HCC) and to evaluate the effectiveness of antiviral therapy in these patients. Materials and methods. This is a prospective and retrospective study. Data from 1870 patients with CHC observed in the hepatology clinic in Ho Chi Minh City (Vietnam) for the years 2010–2015 were analyzed. Results. The average age of detection of HCV infection in patients with hepatocellular carcinoma was 63,1±10,0 years, men — 62,3%. HCC was detected in 9% of patients with chronic hepatitis C (159 people). In 58% of cases, HCC and HCV infection were diagnosed at the same time. In 91,8% patients with HCC, HCV infection was first detected at the age of over 50 years. However, in 46,1% of patients, HCC was diagnosed at stages of the disease, when the possibilities of therapy were limited. Analyzing the effectiveness of antiviral therapy, including sofosbuvir and ribavirin (in 24 weeks), showed that of 75 patients with chronic hepatitis C (genotype 6) without a history of HCC, SVR-24 was registered in 98,7% people; of 11 patients with HCC, only 5 patients (45,5%) achieved SVR-24. Conclusion. Presence of HCC, including after chemotherapy or surgical treatment, is a negative predictor of response to therapy, including sofosbuvir and ribavirin. It is necessary to introduce in Vietnam screening programs for HCV infection to identify patients in the early stages of the disease and to expand access to antiviral drugs for HCV therapy.

Fibrosis scoring has significant impact on the outcome of antiviral therapy for chronic hepatitis C

Endoscopy ◽  
2006 ◽  
Vol 38 (11) ◽  
Author(s):  
A Qasim ◽  
A Grogan ◽  
B Hynes ◽  
H Irish ◽  
D Kevans ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C

Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment

2016 ◽  
Vol 18 (2) ◽  
pp. 155-165 ◽  
Author(s):  
Axel C. Mühlbacher ◽  
John F. P. Bridges ◽  
Susanne Bethge ◽  
Ch.-Markos Dintsios ◽  
Anja Schwalm ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Discrete Choice Experiment ◽  
Discrete Choice ◽  
Choice Experiment
Sign in / Sign up

Export Citation Format

Share Document